Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and chemotherapy in NSCLC with EGFR mutation and BIM deletion
NCT02859077Phase 3Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Aug 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02859077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859077.